Boston Scientific (NYSE:BSX) today claimed a win in an ongoing patent spat with Edwards Lifesciences (NYSE:EW) over transcatheter aortic valve replacement system patents. Marlborough, Mass.-based Boston Scientific said that a jury in the U.S. District Court for the District of Delaware ruled in its favor, finding that their ‘608 patent, related to a transcatheter heart valve sealing skirt, […]
Boston Scientific sues Micro-Tech over endo clip patents
Boston Scientific has filed a lawsuit against Micro-Tech USA and its Chinese manufacturer, Micro-Tech Nanjing, alleging that Micro-Tech infringed three of its patents for endoscopic hemostatic clips. Boston Scientific claims that Micro-Tech’s SureClip hemostasis clip products infringe the patents for its Resolution and Resolution 360 clips, which are designed to control gastrointestinal bleeding. Henry Schein (Melville, N.Y.) is […]
Medtech companies, industry groups shrug off ICIJ’s “Implant Files” report
Medtech companies and industry groups have shrugged off the highly critical, recently released “Implant Files” report from the International Consortium of Investigative Journalists, seeing major medtech company shares stay steady or rise in the wake of its posting. The highly critical “Implant Files” report, which was released early this week, is a collaborative effort overseen […]
Is the medical device industry endangering people?
The highly critical “Implant Files” report overseen by the International Consortium of Investigative Journalists skewers the medtech industry as a whole and singles out particular companies and regulatory agencies for more intense scrutiny. The Implant Files is the second large-scale swipe at the medtech industry this year, following Netflix’s documentary, The Bleeding Edge. It includes six stories about […]
10 of the best performing medical device stocks of 2018
Nearly half of the world’s 100 largest medical device companies saw their stock prices increase by double-digit percentages during the first 10 months of 2018, according to a Medical Design & Outsourcing analysis. The feat is even more amazing considering that October was a rocky month for the Dow Jones Industrial Average, with the year’s […]
Boston Scientific offers $4B for BTG
Boston Scientific (NYSE:BSX) said today that it agreed to offer roughly $4.24 billion to acquire British medical device maker BTG (LON:BTG). The £8.40-per-share offer, worth about £3.3 billion, is a 36.6% premium over BTG’s closing price yesterday and a 51.0% premium over the stock’s 90-day volume-weighted average price, the London-based company said. BTG’s largest division makes devices for oncology […]
Nevro fires back in spinal cord stim patent spat with Boston Scientific
Nevro (NYSE:NVRO) is seeking a reversal and remand for spinal cord stimulation patent infringement case against Boston Scientific (NYSE:BSX) that was ruled on this summer. A legal firm representing the company filed a brief this week seeking to overturn a decision from this summer which found a number of patent claims invalid as indefinite. In mid-July, a […]
Boston Scientific plans $200m restructuring
Boston Scientific (NYSE:BSX) said yesterday that it’s planning a three-year restructuring program that’s slated to cost at least $200 million. The Marlborough, Mass.-based medical device maker said it expects to maintain roughly the same number of workers, although there will be some churn as new jobs are created. “[T]he company does expect some employee attrition and […]
Boston Scientific’s Eluvia drug-eluting stent succeeds in long lesions
Boston Scientific (NYSE:BSX) touted one-year data today from an analysis of its Eluvia drug-eluting vascular stent system, showing that the device is safe and effective in patients with long, complex, calcified lesions. The data were presented by Boston Scientific at the annual Vascular Interventional Advances meeting. Get the full story at our sister site, Drug Delivery Business […]
Boston Scientific CEO talks pricing pressure for drug-eluting stents
On an earnings call with analysts this week, Boston Scientific (NYSE:BSX) CEO Mike Mahoney touted the momentum of his company’s drug-eluting stent portfolio but noted that the technologies continue to face headwinds in the U.S. thanks to pricing pressure. The Mass.-based company reported third-quarter profits of $432 million, or 31¢ per share, on sales of $2.39 billion […]
Boston Scientific slides on Q3 sales miss, lowered outlook
Boston Scientific (NYSE:BSX) shares came under early pressure today after the medical device maker posted third-quarter sales that missed the consensus outlook and lowered its top-line guidance for the rest of the year – despite a 50% bump to its bottom line. Marlborough, Mass.-based Boston Scientific reported profits of $432 million, or 31¢ per share, on […]
- 1
- 2
- 3
- …
- 134
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube